Objective      To evaluate the efficacy and safety of tandem autologous peripheral blood stem cell transplant (APSCT) for lymphoblastic lymphoma.       Methods      Clinic data of 21 patients (median age of 29) with lymphoblastic lymphoma undergoing double APSCT in our hospital from February 2008 to November 2013 were collected and analyzed in this study. By Ann Arbor staging system

they were classified into 5 cases at stage Ⅲ and 16 cases at stage Ⅳ. Before the first transplantation

16 cases achieved complete remission (CR) and 5 cases achieved partial remission (PR). Mobilization regimen was Mit+Vds+VP16+Dex+MTX combined with G-CSF 5 μg/(kg·d). The conditioning regimens for the tandem transplantation were CCNU+VP-16+Ara-c+CTX and IDA+Ara-c+CTX respectively. The interval of the tandem transplantation was 4 to 6 months.       Results      All patients obtained prompt and sustained hematopoietic reconstitution after the tandem transplants. But 3 cases relapsed

4 cases died (2 died of recurrence

1 of disease progression

and 1 of transplantation related mortality)

1 case relapsed and progressed

12 cases were still in disease-free survival

and 4 remained stable after median follow-up of 24 (2～81) months. The 3-year progression-free survival (PFS) was 68.9%

and overall survival (OS) was 72.6%. Multivariate analysis demonstrated that OS and PFS were significantly affected by the age and disease status after first transplantation. The factor influencing OS was CR status or not after first transplantation.       Conclusion      Tandem APSCT is safe and effective for lymphoblastic lymphoma

with well hematopoietic reconstitution and low transplant-related mortality.